| Revenue growth | 23.1% YoY for FY26. |
|---|---|
| Margins | Near-term dilution due to expansion; mature centers at 36-37%. |
| Demand visibility | Strong traction in genomics and advanced radiology segments. |
| Management confidence | High, focus on replicating high-margin model in new territories. |
Growth
FY26 Revenue grew 22.5% to INR 3136M; PAT at INR 314M. EBITDA margins at 31.8%.
Outlook
FY27 Revenue guidance ~15%; EBITDA guidance 33%. Capex planned at INR 70cr for 5 hubs and 8 spokes.
Risks
EBITDA margin compression from 33.8% to 31.8% due to high fixed costs of rapid new center expansion.
Earnings Call filed with NSE, NSE: SURAKSHA. Summary written with AI assistance from the document.
Suraksha Diagnostic Ltd: key numbers
- Share price
- ₹343.30
- Market cap
- ₹1,788 Cr
- Revenue (annual)
- ₹310.4 Cr
- Net profit (annual)
- ₹32.19 Cr
- P/E (TTM)
- 50.0×Sector 57.8×
- Promoter holding
- 49.10%+0.00% QoQ
- FII holding
- 13.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suraksha Diagnostic Ltd
All →Suraksha Diagnostic Annual General Meeting
Suraksha Diagnostic Ltd held its 21st AGM on September 22, 2026. Members adopted financial statements, approved a final dividend, and ratified cost auditor remuneration.
Suraksha Diagnostic Earnings Call Transcript: Key Takeaways
Suraksha Diagnostic reported a robust Q1 FY27 with 21% revenue growth and 40% PAT growth, driven by expansion in West Bengal and Jharkhand and a high-growth genomics segment.
- Call
- Guides 15% growth
Suraksha Diagnostic Investor Presentation: Key Takeaways
Suraksha Diagnostic reported strong Q1 FY27 results with 21% YoY revenue growth and 14.7% PAT margin. Management is aggressively expanding the hub-and-spoke network beyond West Bengal into Jharkhand and Tripura.
Suraksha Diagnostic Q1 FY27 Results: Net Profit ₹12.8 Cr, Up 39.1% YoY
Suraksha Diagnostic Ltd reported revenue from operations of ₹87.6 Cr (+20.7% YoY) and net profit of ₹12.8 Cr (+39.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹12.8 Cr · +39.1% YoY
Suraksha Diagnostic Earnings Call: Key Takeaways
Suraksha Diagnostic reported robust FY26 revenue growth of 23.1% YoY, driven by aggressive regional expansion and a shift toward high-value genomic and specialized radiology testing.
Suraksha Diagnostic Earnings Call: Key Takeaways
Suraksha Diagnostic reported robust FY26 results with 23% revenue growth and 16% EBITDA growth, driven by core diagnostic momentum and expansion in Eastern India.